Loading
AMEXHealthcareMedical - Pharmaceuticals
Latest quote
$0.89
−$0.0007 · -0.08%
Stablecoin Development Corp. specializes in manufacturing and distributing eye and skin health solutions that have undergone rigorous scientific development and proven efficacy in clinical settings. Their product portfolio features prominent brands such as Avenova, NeutroPhase, and DERMAdoctor. This enterprise was established on January 19, 2000, and its main office is situated in Emeryville, California.
Previous close
$0.89
−$0.0007 · -0.08%
Regular session · ET · Market data may be delayed.
Stablecoin Development Corp. specializes in manufacturing and distributing eye and skin health solutions that have undergone rigorous scientific development and proven efficacy in clinical settings. Their product portfolio features prominent brands such as Avenova, NeutroPhase, and DERMAdoctor. This enterprise was established on January 19, 2000, and its main office is situated in Emeryville, California.
Day range
Current $0.89
52-week range
Current $0.89
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
83
Deep Value
Sentiment
49
Mixed
Risk
56
Elevated Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Stablecoin Development Corp. specializes in manufacturing and distributing eye and skin health solutions that have undergone rigorous scientific development and proven efficacy in clinical settings. Their product portfolio features prominent brands such as Avenova, NeutroPhase, and DERMAdoctor. This enterprise was established on January 19, 2000, and its main office is situated in Emeryville, California.
Day range
Current $0.89
52-week range
Current $0.89
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 10.46M USD | 14.4M USD | 10.2M USD |
| Cost of goods sold | 140K USD | 341K USD | 4.37M USD | 6.62M USD | 3.69M USD |
| Gross profit | −140K USD | −341K USD | 6.08M USD | 7.78M USD | 6.52M USD |
| Research and development | — | 42K USD | 34K USD | 174K USD | 44K USD |
| Selling, general, and administrative | 7.45M USD | 7.04M USD | 10.15M USD | 15.29M USD | 15.33M USD |
| Operating expenses | 7.45M USD | 7.04M USD | 10.19M USD | 15.46M USD | 15.38M USD |
| Interest expense | 277K USD | 904K USD | 1.69M USD | — | — |
| Depreciation and amortization | 140K USD | 341K USD | 356K USD | 483K USD | 119K USD |
| Operating income | −7.59M USD | −7.38M USD | −4.1M USD | −7.68M USD | −8.86M USD |
| Net income | −641.98M USD | −7.22M USD | −6.15M USD | −10.61M USD | −5.82M USD |
Company facts updated Sep 5, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
